139 related articles for article (PubMed ID: 8319246)
21. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.
Weiskirch LM; Baumgartel BA; Barker E; Mokyr MB
Cancer Immunol Immunother; 1991; 32(6):353-63. PubMed ID: 1901031
[TBL] [Abstract][Full Text] [Related]
22. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.
Takesue BY; Bartik MM; Mokyr MB
Int J Immunopharmacol; 1987; 9(6):705-17. PubMed ID: 2891627
[TBL] [Abstract][Full Text] [Related]
23. Effect of polyethylene glycol 6000 on the generation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells cultured in the presence or absence of inactivated stimulator tumor cells.
Przepiorka D; Mokyr MB; Dray S
Cancer Res; 1980 Dec; 40(12):4565-70. PubMed ID: 7438090
[TBL] [Abstract][Full Text] [Related]
24. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
25. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
Adler A; Keisari Y; Ofir R
J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
[TBL] [Abstract][Full Text] [Related]
26. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
27. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
Mokyr MB; Barker E
Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
[TBL] [Abstract][Full Text] [Related]
28. Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.
Mokyr MB; Prokhorova A; Rubin M; Bluestone JA
J Immunol; 1994 Oct; 153(7):3123-34. PubMed ID: 8089490
[TBL] [Abstract][Full Text] [Related]
29. Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract.
Kan N; Ohgaki K; Inamoto T; Kodama H
Cancer Immunol Immunother; 1984; 18(3):215-22. PubMed ID: 6334553
[TBL] [Abstract][Full Text] [Related]
30. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA
J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448
[TBL] [Abstract][Full Text] [Related]
31. Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.
Rubin M; Bluestone JA; Newell KA; Prokhorova A; Mokyr MB
J Immunol; 1994 Apr; 152(7):3522-9. PubMed ID: 8144932
[TBL] [Abstract][Full Text] [Related]
32. Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation.
Mokyr MB; Braun DP; Dray S
Cancer Res; 1979 Mar; 39(3):785-92. PubMed ID: 427766
[No Abstract] [Full Text] [Related]
33. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
Bartik MM; Takesue BY; Mokyr MB
Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
[TBL] [Abstract][Full Text] [Related]
34. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
35. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome.
Gorelik L; Mokyr MB
Cancer Immunol Immunother; 1995 Dec; 41(6):363-74. PubMed ID: 8635194
[TBL] [Abstract][Full Text] [Related]
36. Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor.
Mokyr MB; Place AT; Artwohl JE; Valli VE
Cancer Immunol Immunother; 2006 Apr; 55(4):459-68. PubMed ID: 15965646
[TBL] [Abstract][Full Text] [Related]
37. Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB; Pyle JM; Dray S
Cancer Immunol Immunother; 1984; 16(3):162-9. PubMed ID: 6561068
[TBL] [Abstract][Full Text] [Related]
38. Immunoregulation of murine plasmacytoma. I. Generation of anomalous killer cells in vitro by cocultivation with MOPC 104E.
Hayashida I; Hiramoto RN; Shrestha K; Ghanta VK
Cancer Invest; 1989; 7(1):17-26. PubMed ID: 2567619
[TBL] [Abstract][Full Text] [Related]
39. Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
Mokyr MB; Colvin M; Dray S
Int J Immunopharmacol; 1985; 7(1):111-22. PubMed ID: 3922904
[TBL] [Abstract][Full Text] [Related]
40. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. II. Dynamic changes during tumor progression.
Wang WC; Berczi I; Hoffmann EG; Sehon AH
Int J Cancer; 1980 Apr; 25(4):493-501. PubMed ID: 6246008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
